Literature DB >> 2554708

Pharmacologic profile of amlodipine.

R A Burges1, M G Dodd, D G Gardiner.   

Abstract

Amlodipine is a potent calcium antagonist, inhibiting Ca2+-induced contractions of depolarized rat aorta with an IC50 of 1.9 nM. Unlike nifedipine, it displayed very slow association and dissociation with the calcium channel. The ability of amlodipine to inhibit Ca2+-induced contractions was strongly dependent on the K+ concentration present before the contraction, suggesting marked voltage dependence of action. Radioligand-binding studies in cardiac membrane preparations suggested that amlodipine may interact directly with both 1,4-dihydropyridine and diltiazem-binding sites on the calcium channel. Hemodynamic studies in anesthetized and conscious dogs showed that amlodipine is a coronary and peripheral vasodilator with a slow onset and long duration of effect, even when given by intravenous injection; the reflex stimulation of cardiac output, heart rate and myocardial contractility induced by amlodipine was attenuated by propranolol, but no marked negative inotropic or dromotropic effects were observed. Amlodipine was an effective oral antihypertensive agent in rat and dog models of hypertension, and its 24-hour duration of action in hypertensive dogs correlated well with its long plasma half-life in this species. The natriuretic properties displayed by amlodipine may contribute to its use as a first-line drug for the treatment of hypertension.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2554708     DOI: 10.1016/0002-9149(89)90956-9

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  Pharmacokinetics of amlodipine besylate at delivery and during lactation.

Authors:  Jamie L Morgan; Benjamin K Kogutt; Claudia Meek; Elizabeth K Stehel; Donald D McIntire; Jeanne S Sheffield; Scott W Roberts
Journal:  Pregnancy Hypertens       Date:  2018-01-04       Impact factor: 2.899

Review 2.  Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease.

Authors:  D Murdoch; R C Heel
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

Review 3.  Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease.

Authors:  M Haria; A J Wagstaff
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

4.  Efficacy of amlodipine besilate therapy for variant angina: evaluation by 24-hour Holter monitoring.

Authors:  K Watanabe; T Izumi; Y Miyakita; S Koyama; M Ohshima; T Inomata; M Suzuki; M Takahashi; A Shibata
Journal:  Cardiovasc Drugs Ther       Date:  1993-12       Impact factor: 3.727

5.  Effects of cilnidipine on fibrinolysis in chinese hypertensive patients.

Authors:  Hong-Wei Tan; Li Li; Wei Zhang; Zhi-Yong Ma; Xue-Zhen Zhong; Jing-Jing Li; Ying Wang
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

6.  Biochemical changes during amlodipine treatment in hypertensive patients.

Authors:  J E Ahaneku; G O Taylor; O Walker; E O Agbedana; A Sowunmi; L A Salako
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

7.  Direct Visualization of Amlodipine Intervention into Living Cells by Means of Fluorescence Microscopy.

Authors:  Christine Quentin; Rūta Gerasimaitė; Alexandra Freidzon; Levon S Atabekyan; Gražvydas Lukinavičius; Vladimir N Belov; Gyuzel Y Mitronova
Journal:  Molecules       Date:  2021-05-18       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.